Table 1. Clinical and laboratory properties of all patients at baseline .
| Overall (n=138) | ISR (-) (n=98) | ISR (+) (n=40) | P value | |
| Age, y | 61.5 ± 8.8 | 60.6 ± 8.9 | 63.9 ± 8.2 | 0.04 |
| Male, n (%) | 112 (81.2) | 84 (85.7) | 28 (70) | 0.03 |
| BMI, kg/m2 | 24.5 ± 2.8 | 24.2 ± 2.6 | 24.5 ± 2.7 | 0.74 |
| Hypertension, n (%) | 107 (77.5) | 75 (76.5) | 32 (80) | 0.65 |
| Diabetes mellitus, n (%) | 77 (55.8) | 51 (52) | 26 (65) | 0.16 |
| Dyslipidemia, n (%) | 101 (73.2) | 69 (70.4) | 32 (80) | 0.24 |
| Smoking, n (%) | 99 (71.7) | 68 (69.4) | 31 (77.5) | 0.33 |
| CAD, n (%) | 90 (65.2) | 62 (63.3) | 28 (70) | 0.45 |
| Fontaine classification, n( %) | ||||
| Stage II | 85 (61.6) | 67 (68.4) | 18 (45) | 0.02 |
| Stage III | 44 (31.9) | 28 (28.6) | 16 (40) | 0.19 |
| Stage IV | 9 (6.5) | 3 (3.1) | 6 (15) | 0.01 |
| TASC II lesion classification, n( %) | ||||
| Type A | 53 (38.4) | 40 (40.8) | 13 (32.5) | 0.36 |
| Type B | 39 (28.3) | 33 (33.7) | 6 (15) | 0.03 |
| Type C | 34 (24.6) | 23 (23.5) | 11 (27.5) | 0.61 |
| Type D | 12 (8.7) | 2 (2) | 10 (25) | < 0.01 |
| Stent diameter, mm | 8.1 ± 1.03 | 8.2 ± 1.1 | 8.1 ± 1.1 | 0.90 |
| Stent length, mm | 60 [61] | 57 [41.2] | 104 [59.7] | < 0.01 |
| Laboratory parameters | ||||
| Hemoglobin, mg/dL | 13.1 ± 1.6 | 13.2 ± 1.7 | 12.8 ± 1.6 | 0.29 |
| Leukocyte, x109/L | 6.87 ± 1.76 | 6.84 ± 1.78 | 7.10 ± 1.74 | 0.41 |
| Platelet, x109/L | 241.6 ± 39.2 | 236.6 ± 37.3 | 247.1 ± 41.6 | 0.45 |
| MPV, fL | 8.4 ± 1.5 | 8.3 ± 1.6 | 8.7 ± 1.2 | 0.20 |
| eGFR, mL/min/1.73 m2 | 86.9 ± 16.4 | 88.4 ± 16.2 | 83.4 ± 16.5 | 0.10 |
| HbA1c, (%) | 7.48 ± 1.95 | 6.7 ± 1.4 | 9.2 ± 1.9 | < 0.01 |
| CRP/Albumin Ratio (CAR) | 0.16 [0.57] | 0.11 [0.11] | 0.90 [0.58] | < 0.01 |
| Follow-up time, month | 24.7 ± 11 | 24.1 ± 10.3 | 26.4 ± 12.5 | 0.25 |
BMI, body mass index; CAD, coronary artery disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; ISR, in-stent restenosis; MPV, mean platelet volume; TASC, Trans-Atlantic Inter-Society Consensus.